Agreed, Angus, I am very unhappy with this outcome considering they said no more CR. The only reason this may be good is due to the unforeseen growth they are accelerating working capital needs. Hopefully this is a small raise. I am changing my recommendation to a hold, after the Thales f*ckup and now this. Again and again, management look incompetent. I would vote out the majority of management in a heartbeat for better business nouse. Peter may have built the company and technology, but they need experience.
On another note, Bioshares did a great write up on MX1 being a great investment as of yesterday. Well worth a read, calling them a spec buy class A. Saying that Covid-19 is a company making event, and that they are establishing their product in the healthcare field.
MX1 Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
